Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -269,00 | 18,95k | Sale to Issuer | 70,44 | 7,04k | -3,68% |
| 2026-06-02 | Mr. Atabak MokariCFO & Treasurer | -395,00 | 27,82k | Sale to Issuer | 70,44 | 16,13k | -2,39% |
| 2026-06-01 | Mr. Atabak MokariCFO & Treasurer | -40,00k | 2,03M | Derivative Exercise and Sale | 19,26 - 70,00 | 16,13k | - |
| 2026-06-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -12,84k | 895,25k | Automatic Disposition | 69,74 | 2,87M | -0,45% |
| 2026-05-29 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -300,00k | 0,00 | Other Disposition | - | 2,87M | -9,48% |
| 2026-05-27 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 325,00k | Verkauf | 65,00 | 6,23k | -44,52% |
| 2026-05-13 | Mr. Gary Charles RobbChief Business Officer & Secretary | -5,30k | 0,00 | Other Disposition | - | 99,35k | -5,06% |
| 2026-05-05 | Dr. William GuyerChief Development Officer | -20,00k | 603,60k | Derivative Exercise and Sale | 21,65 - 51,83 | 2,23k | - |
| 2026-05-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 2,00M | Automatic Disposition | 50,10 | 2,88M | -1,37% |
| 2026-04-22 | Mr. James N. WilsonIndependent Chairman | -2,00k | 0,00 | Other Disposition | - | 2,40M | -0,08% |
| 2026-04-07 | Dr. William GuyerChief Development Officer | -20,00k | 386,40k | Derivative Exercise and Sale | 21,65 - 40,97 | 2,23k | - |
| 2026-04-06 | Mr. James N. WilsonIndependent Chairman | -5,00k | 0,00 | Other Disposition | - | 2,40M | -0,21% |
| 2026-03-25 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -26,20k | 1,31M | Automatic Disposition | 50,07 | 2,92M | -0,89% |
| 2026-03-20 | Mr. James N. WilsonIndependent Chairman | -4,00k | 0,00 | Other Disposition | - | 2,40M | -0,17% |
| 2026-03-20 | Dr. William GuyerChief Development Officer | -11,77k | 168,97k | Derivative Exercise and Sale | 21,65 - 36,01 | 2,23k | - |
| 2026-03-17 | Mr. George Leonard BakerIndependent Director | 100,00k | 3,31M | Kauf | 33,00 - 33,56 | 5,55M | 1,83% |
| 2026-03-13 | Mr. James N. WilsonIndependent Chairman | -28,00k | 0,00 | Other Disposition | - | 2,41M | -1,15% |
| 2026-03-13 | Mr. David L. MahoneyIndependent Director | -30,00k | 28,35 | Derivative Exercise and Sale | 5,86 - 32,15 | 1,28M | - |
| 2026-03-04 | Dr. William GuyerChief Development Officer | -8,23k | 118,10k | Derivative Exercise and Sale | 21,65 - 35,99 | 2,23k | - |
| 2026-03-03 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -89,00 | 3,20k | Sale to Issuer | 35,97 | 11,23k | -0,79% |
| 2026-03-03 | Mr. Sean MaduckPresident of Endocrinology | -110,00 | 3,96k | Sale to Issuer | 35,97 | 118,69k | -0,09% |
| 2026-03-03 | Mr. Gary Charles RobbChief Business Officer & Secretary | -121,00 | 4,35k | Sale to Issuer | 35,97 | 102,65k | -0,12% |
| 2026-03-03 | Mr. Atabak MokariCFO & Treasurer | -96,00 | 3,45k | Sale to Issuer | 35,97 | 15,26k | -0,63% |
| 2026-02-24 | Mr. James N. WilsonIndependent Chairman | -100,00k | 1,28 | Derivative Exercise and Sale | 3,88 - 36,48 | 2,44M | - |
| 2026-01-08 | Mr. Sean MaduckPresident of Endocrinology | -54,57k | 0,00 | Other Disposition | - | 117,90k | -31,64% |
| 2026-02-09 | Dr. Hazel HuntChief Scientific Officer | 72,03k | 279,48k | Derivative Exercise and Retained Stock | 3,88 | 255,44k | 39,27% |
| 2026-02-09 | Dr. Hazel HuntChief Scientific Officer | -77,97k | 2,92M | Derivative Exercise and Sale | 3,88 - 41,31 | 255,44k | - |
| 2026-02-03 | Dr. William GuyerChief Development Officer | -20,00k | 384,33k | Derivative Exercise and Sale | 21,65 - 40,87 | 1,24k | - |
| 2026-01-27 | Mr. George Leonard BakerIndependent Director | 140,00k | 1,61M | Derivative Exercise and Retained Stock | 5,86 - 15,15 | 5,45M | 2,64% |
| 2026-01-06 | Dr. William GuyerChief Development Officer | -20,00k | 270,66k | Derivative Exercise and Sale | 21,65 - 35,18 | 1,24k | - |
| 2026-01-01 | Mr. George Leonard BakerIndependent Director | 0,00 | 0,00 | Other Disposition | - | 5,31M | 0,00% |
| 2025-12-24 | Mr. Gary Charles RobbChief Business Officer & Secretary | 64,72k | 251,10k | Derivative Exercise and Retained Stock | 3,88 | 101,77k | 174,66% |
| 2025-12-24 | Mr. Gary Charles RobbChief Business Officer & Secretary | -80,28k | 6,40M | Derivative Exercise and Sale | 3,88 - 83,59 | 101,77k | - |
| 2025-12-24 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -550,00k | 23,52M | Derivative Exercise and Sale | 3,88 - 83,59 | 2,94M | - |
| 2025-12-12 | Mr. James N. WilsonIndependent Chairman | -400,00k | 0,00 | Other Disposition | - | 2,35M | -14,57% |
| 2025-12-02 | Dr. William GuyerChief Development Officer | -20,00k | 1,17M | Derivative Exercise and Sale | 21,65 - 80,88 | 1,24k | - |
| 2025-12-02 | Dr. William GuyerChief Development Officer | -787,00 | 0,00 | Other Disposition | - | 1,24k | -38,92% |
| 2025-12-01 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,43M | Derivative Exercise and Sale | 8,27 - 79,52 | 117,90k | - |
| 2025-12-02 | Mr. Sean MaduckPresident of Endocrinology | -135,00 | 10,77k | Sale to Issuer | 79,78 | 117,90k | -0,11% |
| 2025-12-01 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 329,83k | Derivative Exercise and Sale | 13,56 - 79,53 | 10,52k | - |
| 2025-12-02 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -110,00 | 8,78k | Sale to Issuer | 79,78 | 10,52k | -1,03% |
| 2025-12-02 | Mr. Atabak MokariCFO & Treasurer | -118,00 | 9,41k | Sale to Issuer | 79,78 | 14,56k | -0,80% |
| 2025-12-02 | Mr. Gary Charles RobbChief Business Officer & Secretary | -148,00 | 11,81k | Sale to Issuer | 79,78 | 37,05k | -0,40% |
| 2025-12-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 3,19M | Automatic Disposition | 79,77 | 2,70M | -1,46% |
| 2025-11-25 | Dr. William GuyerChief Development Officer | -4,50k | 364,07k | Verkauf | 80,90 | 787,00 | -85,11% |
| 2025-11-17 | Dr. William GuyerChief Development Officer | -5,29k | 0,00 | Other Disposition | - | 787,00 | -87,04% |
| 2025-11-05 | Dr. William GuyerChief Development Officer | -20,00k | 1,07M | Derivative Exercise and Sale | 21,65 - 76,28 | 5,29k | - |
| 2025-11-03 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 300,44k | Derivative Exercise and Sale | 13,56 - 73,65 | 10,28k | - |
| 2025-11-03 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 2,98M | Automatic Disposition | 74,08 - 75,98 | 2,74M | -1,44% |
| 2025-11-03 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,31M | Derivative Exercise and Sale | 8,27 - 73,99 | 117,62k | - |
| 2025-10-10 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 161,61k | Derivative Exercise and Sale | 14,08 - 87,54 | 0,00 | - |
| 2025-10-07 | Dr. William GuyerChief Development Officer | -20,00k | 1,37M | Derivative Exercise and Sale | 21,65 - 89,94 | 5,29k | - |
| 2025-10-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 3,40M | Automatic Disposition | 84,29 - 85,67 | 2,78M | -1,42% |
| 2025-10-01 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 355,97k | Derivative Exercise and Sale | 13,56 - 85,39 | 10,28k | - |
| 2025-10-01 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,54M | Derivative Exercise and Sale | 5,05 - 85,58 | 117,62k | - |
| 2025-09-19 | Dr. William GuyerChief Development Officer | -200,00 | 0,00 | Other Disposition | - | 5,29k | -3,64% |
| 2025-09-10 | Dr. Gillian M. CannonInsider | -7,39k | 0,00 | Other Disposition | - | 0,00 | -100,00% |
| 2025-09-10 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 128,41k | Derivative Exercise and Sale | 14,08 - 72,45 | 0,00 | - |
| 2025-09-04 | Dr. Gillian M. CannonInsider | 7,39k | 169,97k | Derivative Exercise and Retained Stock | 22,99 | 7,39k | - |
| 2025-09-04 | Dr. Gillian M. CannonInsider | -3,61k | 170,03k | Derivative Exercise and Sale | 22,99 - 70,13 | 7,39k | - |
| 2025-09-02 | Dr. William GuyerChief Development Officer | -20,00k | 976,85k | Derivative Exercise and Sale | 21,65 - 70,85 | 5,49k | - |
| 2025-09-02 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 283,45k | Derivative Exercise and Sale | 13,56 - 70,76 | 10,28k | - |
| 2025-09-03 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -189,00 | 13,49k | Sale to Issuer | 71,38 | 10,28k | -1,81% |
| 2025-09-02 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,31M | Derivative Exercise and Sale | 5,05 - 70,84 | 117,62k | - |
| 2025-09-03 | Mr. Sean MaduckPresident of Endocrinology | -233,00 | 16,63k | Sale to Issuer | 71,38 | 117,62k | -0,20% |
| 2025-09-02 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 2,82M | Automatic Disposition | 70,52 - 71,01 | 2,82M | -1,40% |
| 2025-09-03 | Mr. Atabak MokariCFO & Treasurer | -144,00 | 10,28k | Sale to Issuer | 71,38 | 14,32k | -1,00% |
| 2025-09-03 | Mr. Gary Charles RobbChief Business Officer & Secretary | -256,00 | 18,27k | Sale to Issuer | 71,38 | 36,75k | -0,69% |
| 2025-08-22 | Mr. Gary Charles RobbChief Business Officer & Secretary | -5,00k | 336,68k | Derivative Exercise and Sale | 3,88 - 71,27 | 36,51k | - |
| 2025-08-11 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 128,08k | Derivative Exercise and Sale | 14,08 - 72,30 | 0,00 | - |
| 2025-08-08 | Dr. William GuyerChief Development Officer | -35,01k | 1,75M | Derivative Exercise and Sale | 21,65 - 71,77 | 5,49k | - |
| 2025-08-05 | Dr. William GuyerChief Development Officer | -14,00 | 701,68 | Derivative Exercise and Sale | 21,65 - 71,77 | 5,49k | - |
| 2025-08-01 | Mr. Sean MaduckPresident of Endocrinology | -35,01k | 2,20M | Derivative Exercise and Sale | 5,05 - 69,70 | 117,40k | - |
| 2025-06-12 | Mr. Sean MaduckPresident of Endocrinology | -50,02k | 0,00 | Other Disposition | - | 117,40k | -29,88% |
| 2025-08-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 2,74M | Automatic Disposition | 67,81 - 69,65 | 2,86M | -1,38% |
| 2025-08-01 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,82k | 314,17k | Derivative Exercise and Sale | 13,56 - 67,51 | 10,07k | - |
| 2025-07-17 | Mr. Sean MaduckPresident of Endocrinology | -4,79k | 327,61k | Derivative Exercise and Sale | 5,05 - 73,48 | 117,40k | - |
| 2025-07-17 | Dr. William GuyerChief Development Officer | -4,88k | 252,86k | Derivative Exercise and Sale | 21,65 - 73,48 | 5,49k | - |
| 2025-07-17 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -4,08k | 244,26k | Derivative Exercise and Sale | 13,56 - 73,48 | 10,07k | - |
| 2025-07-17 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -615,00 | 45,32k | Automatic Disposition | 73,69 | 2,90M | -0,02% |
| 2025-07-10 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 125,40k | Derivative Exercise and Sale | 14,08 - 71,08 | 0,00 | - |
| 2025-07-01 | Dr. William GuyerChief Development Officer | -100,00 | 5,19k | Derivative Exercise and Sale | 21,65 - 73,51 | 5,49k | - |
| 2025-07-01 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -100,00 | 5,99k | Derivative Exercise and Sale | 13,56 - 73,51 | 10,07k | - |
| 2025-07-01 | Mr. Sean MaduckPresident of Endocrinology | -205,00 | 14,02k | Derivative Exercise and Sale | 5,05 - 73,45 | 117,40k | - |
| 2025-06-16 | Mr. Gary Charles RobbChief Business Officer & Secretary | -3,19k | 225,40k | Verkauf | 70,77 | 36,51k | -8,02% |
| 2025-06-10 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 124,37k | Derivative Exercise and Sale | 14,08 - 70,61 | 0,00 | - |
| 2025-06-10 | Dr. William GuyerChief Development Officer | -20,00k | 1,02M | Derivative Exercise and Sale | 21,65 - 72,75 | 5,49k | - |
| 2025-06-02 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 3,31M | Automatic Disposition | 78,42 - 85,01 | 2,90M | -1,36% |
| 2025-06-02 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 322,42k | Derivative Exercise and Sale | 13,56 - 78,65 | 10,07k | - |
| 2025-06-03 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -441,00 | 31,61k | Sale to Issuer | 71,68 | 10,07k | -4,20% |
| 2025-06-03 | Mr. Gary Charles RobbChief Business Officer & Secretary | -651,00 | 46,66k | Sale to Issuer | 71,68 | 39,69k | -1,61% |
| 2025-06-02 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,48M | Derivative Exercise and Sale | 5,05 - 80,77 | 117,40k | - |
| 2025-06-03 | Mr. Atabak MokariCFO & Treasurer | -519,00 | 37,20k | Sale to Issuer | 71,68 | 14,07k | -3,56% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
